AA
VTGN icon

ALPS Advisors’s VistaGen Therapeutics VTGN Stock Holding History

ALPS Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,075
Closed -$263K – 1094
2022
Q1 		$263K Sell
7,075
-629
-8% -$27.4K ﹤0.01% 785
2021
Q4 		$451K Sell
7,704
-177
-2% -$11.5K 0.01% 553
2021
Q3 		$648K Buy
7,881
+1,660
+27% +$144K 0.01% 468
2021
Q2 		$588K Buy
+6,221
New +$461K 0.01% 500

Other funds holding VTGN

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's VTGN Position: Q2 2022 in Review

ALPS Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2022, closing a stake of 7,075 shares — an estimated $263K sold.

ALPS Advisors first reported a position in VTGN in Q2 2021 and held it in 4 quarters. The position peaked at $648K in Q3 2021. 112 funds tracked by Wall St. Rank hold VTGN as of Q2 2022.

  • ALPS Advisors reported no remaining VistaGen Therapeutics position as of Q2 2022 after selling out during the quarter.
  • ALPS Advisors sold 7,075 VistaGen Therapeutics shares in Q2 2022, an estimated $263K.
  • ALPS Advisors first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 4 quarters.
  • ALPS Advisors's VistaGen Therapeutics position peaked at $648K in Q3 2021.
  • 112 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.